Ortoma AB

Ortoma AB operates with a capital structure that is entirely equity-funded, as evidenced by a debt-to-equity ratio of 0.0. The company's liquidity position is characterized by a current ratio of 3.12, indicating a strong short-term liquidity buffer relative to its current liabilities. However, the company's operating cash flow is negative at -6,364,870 SEK, and free cash flow is also negative at -6,540,980 SEK, suggesting that the company is not generating sufficient cash from operations to sustain its activities without external financing. Profitability metrics are negative across the board. The company reported a net loss of -5,600,160 SEK, with a return on equity of -3.33% and a return on assets of -3.04%. These figures are significantly below the industry median for profitability metrics, indicating that Ortoma is underperforming relative to its peers in the Advanced Medical Equipment & Technology industry. Geographically and segment-wise, the company's revenue is not disclosed by region or product line in the available data. However, the absence of segmental breakdowns suggests that Ortoma may be concentrated in a single geographic market or product offering, which could expose it to higher concentration risk. The company's growth trajectory is also unclear, as the available data does not provide a multi-year revenue history or forward-looking guidance. The company's risk profile is marked by low liquidity and dilution risk, with no immediate filing-based flags detected. However, the negative operating and free cash flows suggest a potential need for future financing, which could lead to dilution if the company issues additional shares. The absence of long-term debt is a positive factor, but the company's reliance on equity financing could increase its cost of capital over time. Recent events and filings do not provide specific details on Ortoma's strategic initiatives or operational changes. Analyst estimates suggest that the company is expected to continue reporting losses, with a mean EPS estimate of -1.02 SEK and a mean EBIT estimate of -39,000,000 SEK. These estimates indicate that the company is not expected to achieve profitability in the near term, and its revenue is projected to remain below analyst expectations.